New combo aims to spare surgery for certain cancer patients

NCT ID NCT06580574

Recruiting now Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a combination of immunotherapy drugs (sintilimab, IBI310, and lenvatinib) can help people with non-metastatic dMMR/MSI-H stomach or colon cancers avoid radical surgery. About 34 participants will receive up to 24 weeks of treatment, and those who achieve a complete clinical response may skip surgery. The goal is to preserve the organ while still controlling the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab, IBI310, and Lenvatinib
What this could lead to: If successful, this could allow some patients with these specific cancers to avoid major surgery by using immunotherapy to eliminate the tumor.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply broadly. Immunotherapy can cause serious side effects, and not all patients will respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER DMMR CANCER GASTRIC CANCER MSI-H

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.